The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
Kelonia's lead program, KLN-1010, is a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 for relapsed/refractory multiple myeloma with clinical data recently highlighted in the 2025 ASH Annual Meeting plenary session
Ac... [7531 chars]